Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage

  • Cathrine Scheepers
  • , Josie Everatt
  • , Daniel G. Amoako
  • , Houriiyah Tegally
  • , Constantinos Kurt Wibmer
  • , Anele Mnguni
  • , Arshad Ismail
  • , Boitshoko Mahlangu
  • , Bronwen E. Lambson
  • , Darren P. Martin
  • , Eduan Wilkinson
  • , James Emmanuel San
  • , Jennifer Giandhari
  • , Nelia Manamela
  • , Noxolo Ntuli
  • , Prudence Kgagudi
  • , Sandile Cele
  • , Simone I. Richardson
  • , Sureshnee Pillay
  • , Thabo Mohale
  • Upasana Ramphal, Yeshnee Naidoo, Zamantungwa T. Khumalo, Gaurav Kwatra, Glenda Gray, Linda Gail Bekker, Shabir A. Madhi, Vicky Baillie, Wesley C. Van Voorhis, Florette K. Treurnicht, Marietjie Venter, Koleka Mlisana, Nicole Wolter, Alex Sigal, Carolyn Williamson, Nei yuan Hsiao, Nokukhanya Msomi, Tongai Maponga, Wolfgang Preiser, Zinhle Makatini, Richard Lessells, Penny L. Moore, Tulio de Oliveira, Anne von Gottberg, Jinal N. Bhiman*
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Global genomic surveillance of SARS-CoV-2 has identified variants associated with increased transmissibility, neutralization resistance and disease severity. Here we report the emergence of the PANGO lineage C.1.2, detected at low prevalence in South Africa and eleven other countries. The initial C.1.2 detection is associated with a high substitution rate, and includes changes within the spike protein that have been associated with increased transmissibility or reduced neutralization sensitivity in SARS-CoV-2 variants of concern or variants of interest. Like Beta and Delta, C.1.2 shows significantly reduced neutralization sensitivity to plasma from vaccinees and individuals infected with the ancestral D614G virus. In contrast, convalescent donors infected with either Beta or Delta show high plasma neutralization against C.1.2. These functional data suggest that vaccine efficacy against C.1.2 will be equivalent to Beta and Delta, and that prior infection with either Beta or Delta will likely offer protection against C.1.2.

Original languageEnglish
Article number1976
JournalNature Communications
Volume13
Issue number1
DOIs
StatePublished - Dec 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage'. Together they form a unique fingerprint.

Cite this